Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]
Frontiers in Oncology, 2021 BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Aini Hyytiäinen +13 more
doaj +4 more sources
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis [PDF]
Journal of Ovarian Research, 2022 Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Chunmei Zhang, Wancheng Zhao
doaj +2 more sources
Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. [PDF]
PLoS ONE, 2013 Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR.
Sabine B Weitensteiner +8 more
doaj +3 more sources
Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case‐Control Study [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis ...
Yen‐Chou Chen +4 more
doaj +2 more sources
Endogenous Matrix-Derived Inhibitors of Angiogenesis
Pharmaceuticals, 2010 Endogenous inhibitors of angiogenesis are proteins or fragments of proteins that are formed in the body, which can inhibit the angiogenic process. These molecules can be found both in the circulation and sequestered in the extracellular matrix (ECM ...
Hans Petter Eikesdal +2 more
doaj +2 more sources
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [PDF]
BMC Pulmonary Medicine, 2023 Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Di Hu +6 more
doaj +2 more sources
Journal of Hematology & Oncology, 2016 Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the
Jing Yu +5 more
doaj +2 more sources
Thromboembolic events associated with angiogenesis inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database [PDF]
Thrombosis JournalBackground Angiogenesis inhibitors are vital in cancer treatment but are increasingly linked to thromboembolic events (TEEs), impacting patient outcomes.
Jintuo Zhou +8 more
doaj +2 more sources
Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]
Frontiers in Oral Health, 2021 Abdelhakim Salem +5 more
doaj +2 more sources
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
Marine Drugs, 2013 Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities.
Ying-Qing Wang, Ze-Hong Miao
doaj +2 more sources